Lenvatinib as a salvage therapy for advanced metastatic medullary thyroid cancer
Open Access
- 17 February 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Journal of Endocrinological Investigation
- Vol. 44 (10), 2139-2151
- https://doi.org/10.1007/s40618-020-01491-3
Abstract
Purpose Patients with advanced progressive metastatic medullary thyroid cancer (MTC), show poor prognosis and few available systemic therapeutic options. After the loss of clinical benefit with other tyrosine kinase inhibitors (TKI), we evaluated the use of lenvatinib as salvage therapy. Methods Ten patients who experienced the loss of clinical benefit after treatment with at least one previous TKI, were treated with lenvatinib. We assessed patient’s response immediately before, at the first (first-EV) and last (last-EV) evaluation, after the beginning of treatment. Results At first-EV, one patient died, while all the remaining 9 showed a stable disease (SD) in the target lesions. At last-EV, SD was still observed in seven patients, while partial response (PR) and progressive disease (PD), in one patient each. Conversely, analyzing all target and non-target lesions, at first-EV, we observed PR in one patient and SD in eight patients. At last-EV, PR was shown in two patients and SD was shown in seven. Bone metastases showed stable disease control at both first-EV and last-EV in only approximately 60% of cases. Tumor markers (CTN and CEA) decreased at first-EV, while they increased at last-EV. Seven patients experienced at least one dose reduction during treatment with lenvatinib. Conclusions In this real-life clinical experience, lenvatinib showed interesting results as salvage therapy in patients with advanced progressive metastatic MTC patients. Its usefulness could be effective in patients without any other available treatment, because previously used or unsuitable, especially with negative RET status with no access to the new highly selective targeted therapies.Keywords
Funding Information
- Associazione Italiana per la Ricerca sul Cancro (project code 21790)
- Agenzia Italiana del Farmaco, Ministero della Salute (project code AIFA-2016- 02365049)
This publication has 24 references indexed in Scilit:
- Elevated level of serum carbohydrate antigen 19.9 as predictor of mortality in patients with advanced medullary thyroid cancerActa Endocrinologica, 2015
- Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid CarcinomaThyroid®, 2015
- Multitargeting strategy using lenvatinib and golvatinib: Maximizing anti‐angiogenesis activity in a preclinical cancer modelCancer Science, 2014
- Cabozantinib in Progressive Medullary Thyroid CancerJournal of Clinical Oncology, 2013
- Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III TrialJournal of Clinical Oncology, 2012
- Phase II Study of Safety and Efficacy of Motesanib in Patients With Progressive or Symptomatic, Advanced or Metastatic Medullary Thyroid CancerJournal of Clinical Oncology, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Modes of resistance to anti-angiogenic therapyNature Reviews Cancer, 2008
- Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling timesActa Endocrinologica, 2008
- Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patientsClinical Endocrinology, 1998